Effects of cilostazol on lipid and fatty acid metabolism

Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. Randomised, double-blind, placebo-controlled trials in 2702 patients with intermittent claudication demonstrated that cilostazol significantly increased walking distances compared...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental medicine 2005-03, Vol.4 (4), p.170-173
Hauptverfasser:	Nakamura, N, Osawa, H, Yamabe, H, Okumura, K, Hamazaki, T
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Atherosclerosis - drug therapy Clinical trials Double-Blind Method Fatty acids Fatty Acids - metabolism Female Humans Intermittent Claudication - drug therapy Lipid Metabolism - drug effects Lipids Male Metabolism Phosphodiesterase Inhibitors - pharmacology Phosphodiesterase Inhibitors - therapeutic use Tetrazoles - pharmacology Tetrazoles - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. Randomised, double-blind, placebo-controlled trials in 2702 patients with intermittent claudication demonstrated that cilostazol significantly increased walking distances compared with placebo. Furthermore, the agent has beneficial effects on the serum lipid profile and fatty acid composition in plasma. Consequently, cilostazol may be useful to prevent atherosclerosis from progressing by ameliorating lipid and fatty acid metabolism.
ISSN:	1591-8890 1591-9528
DOI:	10.1007/s10238-004-0052-1